Your browser doesn't support javascript.
loading
Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model.
Crossley, Rachel A; Matz, Alyssa; Dew, Terry; Kalinauskas, Ashley; Faucette, Nicole; Poff, Brad; Silbart, Lawrence K; Suckow, Mark A.
Afiliación
  • Crossley RA; Department of Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, CT, U.S.A.
  • Matz A; Department of Molecular and Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT, U.S.A.
  • Dew T; Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
  • Kalinauskas A; Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
  • Faucette N; Department of Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, CT, U.S.A.
  • Poff B; Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
  • Silbart LK; Department of Molecular and Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT, U.S.A.
  • Suckow MA; Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A. msuckow@uky.edu.
Anticancer Res ; 39(4): 1699-1703, 2019 Apr.
Article en En | MEDLINE | ID: mdl-30952708
ABSTRACT
BACKGROUND/

AIM:

Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. MATERIALS AND

METHODS:

An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis.

RESULTS:

A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention.

CONCLUSION:

Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Enfermedades de los Perros / Inmunoterapia / Antígenos de Neoplasias / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Enfermedades de los Perros / Inmunoterapia / Antígenos de Neoplasias / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos